- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02389699
Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ
March 10, 2015 updated by: Liao Ning
Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ
Radiation therapy uses high-energy x-rays to damage tumor cells.
Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.The clinical trial is conducting to compare the effectiveness of radiation therapy during surgery and whole-breast radiation therapy in treating women who have undergone breast-conversing surgery for Intermediate or high grade ductal carcinoma in situ breast cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
74
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Academy of Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Tumor diameter < 5 cm
- Intermediate or high grade ductal carcinoma in situ
- Informed consent
Exclusion Criteria:
- No informed consent
- Tumor size > 3,5 cm
- Low grade ductal carcinoma in situ
- Invasive carcinoma
- No indication for a boost
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intraoperative Radiotherapy
Boost with 20 Gy during BCS, EBRT with 46-50 Gy
|
Boost with 20 Gy during BCS, EBRT with 46-50 Gy
|
|
ACTIVE_COMPARATOR: whole breast radiation
WRT:whole breast radiation after BCS with 46-50 Gy
|
whole breast radiation after BCS with 46-50 Gy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ipsilateral breast tumor recurrence rate after surgery within five years
Time Frame: Within 5 years after surgery
|
Within 5 years after surgery,we should evaluate ipsilateral breast tumor recurrence and Disease free survival as the most important outcome measure
|
Within 5 years after surgery
|
|
Disease free survival after surgery within five years
Time Frame: Within 5 years after surgery
|
Within 5 years after adjuvant chemotherapy,we should evaluateDisease free survival(DFS) rates as thet important outcome measure.
|
Within 5 years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival after surgery within ten years
Time Frame: Within ten years after surgery
|
After surgery,we should evaluate overall survival (OR)rates as the secondary important outcome measure.
|
Within ten years after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (ANTICIPATED)
June 1, 2019
Study Completion (ANTICIPATED)
June 1, 2024
Study Registration Dates
First Submitted
March 10, 2015
First Submitted That Met QC Criteria
March 10, 2015
First Posted (ESTIMATE)
March 17, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
March 17, 2015
Last Update Submitted That Met QC Criteria
March 10, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Breast Carcinoma In Situ
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Intraductal, Noninfiltrating
Other Study ID Numbers
- GGHBCRG-IORT-WRT-DCIS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Dana-Farber Cancer InstituteIncyte CorporationActive, not recruitingInflammatory Breast Cancer (IBC)United States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCCompletedBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Xijing HospitalActive, not recruitingBreast Cancer | Breast Cancer (Triple Negative Breast Cancer (TNBC))China
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
BerGenBio ASAMerck Sharp & Dohme LLCTerminatedTriple Negative Breast Cancer | Inflammatory Breast Cancer Stage IVSpain, United States, United Kingdom, Norway
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Beaumont HospitalRecruitingRobotic Surgery | Breast Reconstruction | DIEP Flap Breast Reconstruction | Breast Cancer, Breast NeoplasmsIreland
Clinical Trials on Intraoperative Radiotherapy
-
University of California, San FranciscoCarl Zeiss Meditec AGActive, not recruitingStage IA Breast Cancer | Stage IIA Breast CancerUnited States
-
Xiangyun ZongTerminatedQuality of LifeChina
-
Parc de Salut MarRecruiting
-
Liao NingRecruitingBreast NeoplasmsChina
-
Universita di VeronaSuspendedBorderline Resectable Pancreatic CancerItaly
-
Universitätsmedizin MannheimRecruitingBrain MetastasesGermany
-
European Institute of OncologyCompletedCarcinoma BreastItaly
-
Peter MacCallum Cancer Centre, AustraliaCompletedMalignant Rectal Neoplasm | Recurrent TumorAustralia
-
Universitätsmedizin MannheimCompleted
-
Wake Forest University Health SciencesWithdrawnInvasive Ductal Breast Cancer | Carcinoma Breast Stage IUnited States